This site is intended for healthcare professionals
  • Home
  • /
  • Journals
  • /
  • Cancer-associated thrombosis
  • /
  • Direct Oral Anticoagulants and Cancer-Associated T...
Journal

Direct Oral Anticoagulants and Cancer-Associated Thrombosis Management. Where Do We Stand in 2019?

Read time: 1 mins
Published:24th Jun 2019
Author: Ramacciotti E, Agati LB, Caffaro RA, Volpiani GG, Lopes RD, Comerota AJ et al.
Availability: Free full text
Ref.:Clin Appl Thromb Hemost. 2019 Jan-Dec;25:1076029619856433.
DOI:10.1177/1076029619856433.
Direct Oral Anticoagulants and Cancer-Associated Thrombosis Management. Where Do We Stand in 2019?


Direct oral anticoagulants (DOACs) are now widely used for the management of venous thromboembolism (VTE) that now includes cancer-associated thrombosis. This review summarizes recent data on VTE prophylaxis and treatment, new challenges, guidelines, and updates as well as the current place for DOACs on the emerging cancer-associated VTE management landscape.

Read abstract on library site Access full article